Missed GME or NVDA? Don’t Miss the Next One.
Join 5,000+ investors using Ticker Nerd’s Market Radar to stay ahead of major market moves, analyst upgrades, and trending opportunities — for free.
EPRX Stock Forecast 2025-2026
$4.24
Current Price
$152.99M
Market Cap
Buy 4
Hold 0
Sell 0
Wall St Analyst Ratings
Distance to EPRX Price Targets
+183.0%
To High Target of $12.00
+183.0%
To Median Target of $12.00
+183.0%
To Low Target of $12.00
EPRX Price Momentum
+9.8%
1 Week Change
+8.7%
1 Month Change
+63.1%
1 Year Change
+33.8%
Year-to-Date Change
-5.4%
From 52W High of $4.48
+92.7%
From 52W Low of $2.20
📊 TOP ANALYST CALLS
Did EPRX Make This Month's Elite Buy List?
We don't follow just any analyst — only the top 3% with a proven track record make our cut. See if Eupraxia is one of their latest high-conviction picks.
Latest EPRX Stock Price Targets & Analyst Predictions
Based on our analysis of 1 Wall Street analyst, EPRX has a bullish consensus with a median price target of $12.00 (ranging from $12.00 to $12.00). The overall analyst rating is Strong Buy (10.0/10). Currently trading at $4.24, the median forecast implies a 183.0% upside. This outlook is supported by 4 Buy, 0 Hold, and 0 Sell ratings.
Please note that analyst price targets are forward-looking estimates subject to substantial market, economic, and company-specific risks. Past performance does not guarantee future results, and actual stock performance may materially differ from these projections. Investors should conduct their own due diligence and consider their investment objectives and risk tolerance before making investment decisions.
EPRX Analyst Ratings
4
Buy
0
Hold
0
Sell
EPRX Price Target Range
Low
$12.00
Average
$12.00
High
$12.00
Current: $4.24
Latest EPRX Stock Forecasts by Analyst
These are the latest 20 analyst ratings and price targets for EPRX.
| Date | Firm | Analyst | Rating | Change | Price Target |
|---|---|---|---|---|---|
| Nov 14, 2024 | Rodman & Renshaw | Brandon Folkes | Buy | Initiates | $9.00 |
Eupraxia Pharmaceuticals Inc. (EPRX) Competitors
The following stocks are similar to Eupraxia based on their market capitalization and industry sector. These similar stocks potentially provide investors with alternative investment opportunities within the same market segment.
Eupraxia Pharmaceuticals Inc. (EPRX) Financial Data
Eupraxia Pharmaceuticals Inc. has a market capitalization of $152.99M with a P/E ratio of -5.9x. The company generates $0 in trailing twelve-month revenue with a 0.0% profit margin.
Revenue growth is N/A quarter-over-quarter, while maintaining an operating margin of 0.0% and return on equity of -116.8%.
Valuation Metrics
Market Cap
$152.99M
Enterprise Value
$154.73M
P/E Ratio
-5.9x
PEG Ratio
0.2x
Price/Sales
0.0x
Growth & Margins
Revenue Growth (YoY)
N/A
Gross Margin
N/A
Operating Margin
0.0%
Net Margin
0.0%
EPS Growth
N/A
Financial Health
Cash/Price Ratio
+18.1%
Current Ratio
13.0x
Debt/Equity
0.2x
ROE
-116.8%
ROA
-52.1%
💡 SKIP THE NOISE
97% of Analyst Ratings Go Nowhere
We filter thousands of calls to find the few that actually matter. Get the top analyst buy ratings — tracked and updated every Monday and Thursday.
Eupraxia Pharmaceuticals Inc. (EPRX) Business Model
About Eupraxia Pharmaceuticals Inc.
What They Do
Develops innovative drug delivery technologies.
Business Model
The company focuses on creating long-lasting medications for pain management and chronic diseases, generating revenue through the development and commercialization of its drug delivery products, such as EP-104IAR for osteoarthritis treatment.
Additional Information
Founded in Victoria, Canada, Eupraxia Pharmaceuticals targets significant healthcare sectors with unmet medical needs, emphasizing innovation in drug therapies to improve patient compliance and quality of life.
Company Information
Sector
Healthcare
Industry
Biotechnology
Employees
33
CEO
Dr. James A. Helliwell FRCPC, M.D.
Country
Canada
IPO Year
2024
Website
www.eupraxiapharma.comEupraxia Pharmaceuticals Inc. (EPRX) Latest News & Analysis
Latest News
Eupraxia Pharmaceuticals Announces Voting Results from Annual General and Special Meeting of Shareholders
18 days ago
Quick Summary
Eupraxia Pharmaceuticals Inc. (TSX: EPRX, NASDAQ: EPRX) announced the successful election of all six board nominees during its Annual General Meeting on June 2, 2025.
Why It Matters
Eupraxia’s board election signifies management stability, which can foster investor confidence. The focus on drug delivery innovation may enhance future growth prospects and market positioning.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Quick Summary
Phase 1b/2a RESOLVE data indicates EP-104GI may significantly enhance treatment options for Eosinophilic Esophagitis (EoE) patients.
Why It Matters
Positive Phase 1b/2a results for EP-104GI indicate potential market growth in treating EoE, suggesting possible revenue increases for the company and impacting stock performance.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Quick Summary
Eupraxia Pharmaceuticals will host a virtual event to discuss the Phase 1b/2a RESOLVE study of EP-104GI for treating Eosinophilic Esophagitis (EoE).
Why It Matters
Eupraxia's KOL event highlights progress in developing EP-104GI for EoE, potentially influencing stock performance and investor sentiment based on clinical trial outcomes.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Eupraxia Pharmaceuticals to Present at Investor and Scientific Conferences in April and May
1 month ago
Quick Summary
Eupraxia Pharmaceuticals (NASDAQ: EPRX, TSX: EPRX) will present at the OARSI World Congress on April 24-27, 2025, showcasing data on EP-104IAR for knee osteoarthritis from a Phase 2 study.
Why It Matters
Eupraxia's presentation at key conferences highlights its advancements in addressing osteoarthritis, signaling potential growth and innovation, which can attract investor interest and influence stock performance.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Quick Summary
Eupraxia Pharmaceuticals (NASDAQ:EPRX, TSX:EPRX) reported its Q4 2024 financial results. The company focuses on drug delivery using its DiffuSphere™ technology.
Why It Matters
Eupraxia's Q4 2024 financial results reveal its progress in drug delivery technology, impacting future valuations and potential growth, which are critical for investor decision-making.
Source: PRNewsWire
Market Sentiment:
Neutral
Quick Summary
Eupraxia Pharmaceuticals reported positive results from its RESOLVE trial for EP-104GI, showing significant symptom and tissue health improvements in Cohort 6. Cohort 7 is fully enrolled, with data due in Q2 2025.
Why It Matters
Eupraxia's positive clinical trial results for EP-104GI suggest significant advancements in treating eosinophilic esophagitis, indicating potential market value growth and investor interest.
Source: PRNewsWire
Market Sentiment:
Neutral
Frequently Asked Questions About EPRX Stock
What is Eupraxia Pharmaceuticals Inc.'s (EPRX) stock forecast for 2025?
Based on our analysis of 1 Wall Street analysts, Eupraxia Pharmaceuticals Inc. (EPRX) has a median price target of $12.00. The highest price target is $12.00 and the lowest is $12.00.
Is EPRX stock a good investment in 2025?
According to current analyst ratings, EPRX has 4 Buy ratings, 0 Hold ratings, and 0 Sell ratings. The stock is currently trading at $4.24. Always conduct your own research and consider your investment goals before making investment decisions.
What is the long-term price prediction for EPRX stock?
Wall Street analysts predict EPRX stock could reach $12.00 in the next 12 months. This represents a 183.0% increase from the current price of $4.24. Please note that this is a projection by Wall Street analysts and not a guarantee.
What is Eupraxia Pharmaceuticals Inc.'s business model?
The company focuses on creating long-lasting medications for pain management and chronic diseases, generating revenue through the development and commercialization of its drug delivery products, such as EP-104IAR for osteoarthritis treatment.
What is the highest forecasted price for EPRX Eupraxia Pharmaceuticals Inc.?
The highest price target for EPRX is $12.00 from at , which represents a 183.0% increase from the current price of $4.24.
What is the lowest forecasted price for EPRX Eupraxia Pharmaceuticals Inc.?
The lowest price target for EPRX is $12.00 from at , which represents a 183.0% increase from the current price of $4.24.
What is the overall EPRX consensus from analysts for Eupraxia Pharmaceuticals Inc.?
The overall analyst consensus for EPRX is bullish. Out of 1 Wall Street analysts, 4 rate it as Buy, 0 as Hold, and 0 as Sell, with a median price target of $12.00.
How accurate are EPRX stock price projections?
Stock price projections, including those for Eupraxia Pharmaceuticals Inc., are based on various factors including financial models, market conditions, and analyst forecasts. While these predictions provide valuable insights, they should be considered alongside your own research and risk tolerance.
Important Disclaimer
The information provided by Ticker Nerd is for educational and informational purposes only. It should not be considered financial or investment advice. Past performance is not indicative of future results. Always conduct your own research and consult with a qualified financial advisor before making any investment decisions. Analyst ratings and price forecasts are sourced from Wall St analysts and other experts. These projections are speculative and do not guarantee future stock performance.
Last updated: June 20, 2025 6:55 PM UTC